11-dehydro Thromboxane B2 ELISA Kit - Monoclonal, Cayman Chemical Company
Supplier: Cayman Chemical Company
For the quantification of 11-dehydro TXB2 in urine and other sample matrices.
- Detect 11-dehydro TXB2, a stable urinary metabolite of TXA2 and TXB2
- Assay 24 samples in triplicate or 36 samples in duplicate
- Measure 11-dehydro TXB2 levels down to 34 pg/mL
- Incubation: 18 hours | Development: 60 – 90 minutes | Read: Colorimetric at 405 – 420 nm
- Midpoint: 50% B/B0: 80 – 160 pg/mL
Thromboxane A2 (TXA2), produced from arachidonic acid, causes irreversible platelet aggregation, vascular, and bronchial smooth muscle contraction. TXA2 is rapidly hydrolyzed non-enzymatically to form TXB2. However, most of the TXB2 measured in the plasma or urine of healthy individuals is due to ex vivo platelet activation or intra-renal production, and normal concentrations of circulating TXB2 are extremely low (1 – 2 pg/mL) and highly transient (t½= 5 – 7 minutes). 11-dehydro TXB2 is a metabolite of TXB2 (not formed by platelets or the kidney) with a circulating half-life (t½) of 45 minutes. Its measurement in plasma or urine will give a time-integrated indication of TXA2 production and is recommended to estimate TXA2 levels to circumvent measurement complications associated with TXB2. Cayman’s 11-dehydro TXB2 ELISA Kit is a competitive assay that can be used for quantification of 11-dehydro TXB2 in urine and other sample matrices. Normal plasma levels of 11-dehydro TXB2 (1 – 2 pg/mL) are below the detection limit of this assay (16 pg/mL), so plasma samples must be purified and concentrated prior to analysis. Urine samples should be diluted appropriately before assaying. There is evidence suggesting that 11-dehydro TXB2 can be formed non-enzymatically following platelet activation, so it is important to process plasma samples quickly to prevent artifactual formation of 11-dehydro TXB2.
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...